GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Panacea Life Sciences Holdings Inc (OTCPK:PLSH) » Definitions » Peter Lynch Fair Value

PLSH (Panacea Life Sciences Holdings) Peter Lynch Fair Value : N/A (As of Oct. 31, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Panacea Life Sciences Holdings Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.


The historical rank and industry rank for Panacea Life Sciences Holdings's Peter Lynch Fair Value or its related term are showing as below:



PLSH's Price-to-Peter-Lynch-Fair-Value is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.355
* Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


Panacea Life Sciences Holdings Peter Lynch Fair Value Historical Data

The historical data trend for Panacea Life Sciences Holdings's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Panacea Life Sciences Holdings Peter Lynch Fair Value Chart

Panacea Life Sciences Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Peter Lynch Fair Value
- - - -

Panacea Life Sciences Holdings Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Panacea Life Sciences Holdings's Peter Lynch Fair Value

For the Drug Manufacturers - Specialty & Generic subindustry, Panacea Life Sciences Holdings's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Panacea Life Sciences Holdings's Price-to-Peter-Lynch-Fair-Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Panacea Life Sciences Holdings's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where Panacea Life Sciences Holdings's Price-to-Peter-Lynch-Fair-Value falls into.



Panacea Life Sciences Holdings Peter Lynch Fair Value Calculation

Panacea Life Sciences Holdings's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* N/A *-0.414
=N/A

Panacea Life Sciences Holdings's EPS without NRI for the trailing twelve months (TTM) uses the latest annual data, which was $-0.41.

* Note that for companies that do not have enough quarterly data to calculate the 5-Year TTM EBITDA Growth Rate, we use the annual data for the calculation.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


Panacea Life Sciences Holdings  (OTCPK:PLSH) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 0 instead of 15 in this case.

Panacea Life Sciences Holdings's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=0.09/N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Panacea Life Sciences Holdings Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of Panacea Life Sciences Holdings's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Panacea Life Sciences Holdings Business Description

Traded in Other Exchanges
N/A
Address
5910 S University Boulevard, C18-193, Greenwood Village, CO, USA, 80121
Panacea Life Sciences Holdings Inc is a holding company organized as a plant-based natural health ingredient and product company, specializing in the development, manufacturing, research, and distribution of products and rapidly growing natural health and wellness market segment for both humans and animals. Its products are CBD Softgels, CBD Tablets, CBD Topicals, CBD Skin Care, CBD Tinctures, CBD Edibles, CBD Patches, CBD Pets, and PPE.
Executives
Leslie Buttorff director, 10 percent owner, officer: CHIEF EXECUTIVE OFFICER 16194 W 45TH DRIVE, GOLDEN CO 80403
Janice Nerger director 5910 S UNIVERSITY BLVD., C18-193, GREENWOOD VILLAGE CO 80121
Nathan Joel Berman officer: CONTROLLER & PRIN ACTNG OFCR 16194 W 45TH DRIVE, GOLDEN CO 80403
22nd Century Group, Inc. 10 percent owner 8560 MAIN STREET, SUITE 4, WILLIAMSVILLE NY 14221
Harvey J Kesner 10 percent owner 65 E. 55TH STREET, NEW YORK NY 10022
Lawrence Wert director 170 NUTTALL RD, RIVERSIDE IL 60546
Chesne Derek Du officer: Chief Growth Officer 80 NE 4TH AVENUE, SUITE 28, DELRAY BEACH FL 33483
Alvaro Daniel Alberttis director 80 NE 4TH AVENUE, SUITE 28, DELRAY BEACH FL 33483
Vladislav Yampolsky director, 10 percent owner 332 PLAZA REAL, BOCA RATON FL 33432
Steven A Schwartz director 332 PLAZA REAL, BOCA RATON FL 33432
Andrew L. Johnson officer: Chief Strategy Officer 80 NE 4TH AVE. SUITE 28, DELRAY BEACH FL 33483
Emiliano Angel Aloi officer: President 510 SUNSHINE DRIVE, DELRAY BEACH FL 33444
Jonathan Gilbert director, officer: Executive Chairman 36 SYCAMORE LANE, ROSALYN HEIGHTS NY 11577
John C Price director 4721 IRONTON STREET, BUILDING A, DENVER CO 80239
Kevin James Esval director NEURO HITECH INC, ONE PENN PLAZA STE 1503, NEW YORK NY 10019

Panacea Life Sciences Holdings Headlines

From GuruFocus

Panacea Announces Letter of Intent to Acquire N7 Enterprises, Inc.

By Stock market mentor Stock market mentor 01-23-2023